JP2013516427A - 大豆加工ストリームから単離される精製ボーマン・バークプロテアーゼインヒビタープロテイン - Google Patents
大豆加工ストリームから単離される精製ボーマン・バークプロテアーゼインヒビタープロテイン Download PDFInfo
- Publication number
- JP2013516427A JP2013516427A JP2012547309A JP2012547309A JP2013516427A JP 2013516427 A JP2013516427 A JP 2013516427A JP 2012547309 A JP2012547309 A JP 2012547309A JP 2012547309 A JP2012547309 A JP 2012547309A JP 2013516427 A JP2013516427 A JP 2013516427A
- Authority
- JP
- Japan
- Prior art keywords
- bbi
- seq
- protein
- product
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title claims abstract description 19
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 title claims abstract description 10
- 235000010469 Glycine max Nutrition 0.000 title description 219
- 244000068988 Glycine max Species 0.000 title description 27
- 238000012545 processing Methods 0.000 title description 13
- 108091006086 inhibitor proteins Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 136
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 136
- 238000000034 method Methods 0.000 claims abstract description 123
- 210000003205 muscle Anatomy 0.000 claims description 41
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 230000000694 effects Effects 0.000 claims description 37
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 22
- 239000002158 endotoxin Substances 0.000 claims description 21
- 108090000317 Chymotrypsin Proteins 0.000 claims description 20
- 229960002376 chymotrypsin Drugs 0.000 claims description 20
- 101710137926 Chymotrypsin inhibitor Proteins 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 18
- 229940122644 Chymotrypsin inhibitor Drugs 0.000 claims description 17
- 239000003541 chymotrypsin inhibitor Substances 0.000 claims description 17
- 101710162629 Trypsin inhibitor Proteins 0.000 claims description 16
- 239000002753 trypsin inhibitor Substances 0.000 claims description 16
- 108090000631 Trypsin Proteins 0.000 claims description 15
- 102000004142 Trypsin Human genes 0.000 claims description 15
- 229940122618 Trypsin inhibitor Drugs 0.000 claims description 15
- 239000012588 trypsin Substances 0.000 claims description 15
- 230000001575 pathological effect Effects 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 230000036559 skin health Effects 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000037896 autoimmune cutaneous disease Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 229940121649 protein inhibitor Drugs 0.000 claims 1
- 239000012268 protein inhibitor Substances 0.000 claims 1
- 108010046377 Whey Proteins Proteins 0.000 description 175
- 102000007544 Whey Proteins Human genes 0.000 description 170
- 239000005862 Whey Substances 0.000 description 147
- 235000018102 proteins Nutrition 0.000 description 124
- 239000000047 product Substances 0.000 description 113
- 239000012528 membrane Substances 0.000 description 73
- 238000000926 separation method Methods 0.000 description 58
- 239000000203 mixture Substances 0.000 description 53
- 230000008569 process Effects 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 40
- 229910052500 inorganic mineral Inorganic materials 0.000 description 38
- 239000011707 mineral Substances 0.000 description 38
- 235000010755 mineral Nutrition 0.000 description 38
- 238000011084 recovery Methods 0.000 description 33
- 108010073771 Soybean Proteins Proteins 0.000 description 30
- 229940001941 soy protein Drugs 0.000 description 29
- 235000021119 whey protein Nutrition 0.000 description 29
- 238000001914 filtration Methods 0.000 description 28
- 239000000243 solution Substances 0.000 description 24
- 229920001542 oligosaccharide Polymers 0.000 description 23
- 150000002482 oligosaccharides Chemical class 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 22
- 239000012466 permeate Substances 0.000 description 22
- 238000000108 ultra-filtration Methods 0.000 description 21
- 238000001556 precipitation Methods 0.000 description 20
- 238000005342 ion exchange Methods 0.000 description 19
- 235000000346 sugar Nutrition 0.000 description 19
- 235000013361 beverage Nutrition 0.000 description 18
- 235000021374 legumes Nutrition 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 230000031787 nutrient reservoir activity Effects 0.000 description 16
- 150000008163 sugars Chemical class 0.000 description 16
- 235000013305 food Nutrition 0.000 description 15
- 239000003456 ion exchange resin Substances 0.000 description 15
- 229920003303 ion-exchange polymer Polymers 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 238000001728 nano-filtration Methods 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 239000012141 concentrate Substances 0.000 description 14
- 235000008504 concentrate Nutrition 0.000 description 14
- 238000005374 membrane filtration Methods 0.000 description 14
- 238000001471 micro-filtration Methods 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 238000011026 diafiltration Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000000835 fiber Substances 0.000 description 13
- 239000012530 fluid Substances 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 244000046052 Phaseolus vulgaris Species 0.000 description 12
- 229920004929 Triton X-114 Polymers 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 239000012535 impurity Substances 0.000 description 12
- 238000002955 isolation Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 210000003141 lower extremity Anatomy 0.000 description 12
- 244000005700 microbiome Species 0.000 description 12
- 235000013379 molasses Nutrition 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000006057 Non-nutritive feed additive Substances 0.000 description 10
- 239000000919 ceramic Substances 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000011148 porous material Substances 0.000 description 10
- 210000002027 skeletal muscle Anatomy 0.000 description 10
- 239000001509 sodium citrate Substances 0.000 description 10
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 238000000502 dialysis Methods 0.000 description 9
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 230000008020 evaporation Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 201000000585 muscular atrophy Diseases 0.000 description 9
- 238000001223 reverse osmosis Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 206010028289 Muscle atrophy Diseases 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 239000012510 hollow fiber Substances 0.000 description 8
- 210000001087 myotubule Anatomy 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 208000029578 Muscle disease Diseases 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000002121 nanofiber Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 229940071440 soy protein isolate Drugs 0.000 description 7
- 235000007319 Avena orientalis Nutrition 0.000 description 6
- 244000075850 Avena orientalis Species 0.000 description 6
- 240000007594 Oryza sativa Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 6
- 244000062793 Sorghum vulgare Species 0.000 description 6
- 241000209149 Zea Species 0.000 description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000005822 corn Nutrition 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 6
- 239000010703 silicon Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000021307 Triticum Nutrition 0.000 description 5
- 241000209140 Triticum Species 0.000 description 5
- 240000001417 Vigna umbellata Species 0.000 description 5
- 235000011453 Vigna umbellata Nutrition 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000003729 cation exchange resin Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000009295 crossflow filtration Methods 0.000 description 5
- 230000003412 degenerative effect Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 150000002772 monosaccharides Chemical class 0.000 description 5
- 230000020763 muscle atrophy Effects 0.000 description 5
- 229920002492 poly(sulfone) Polymers 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- 240000005979 Hordeum vulgare Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- -1 KTI Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 238000005377 adsorption chromatography Methods 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012627 chemopreventive agent Substances 0.000 description 4
- 229940124443 chemopreventive agent Drugs 0.000 description 4
- 238000013375 chromatographic separation Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 238000005191 phase separation Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- GUIBZZYABLMRRD-CQSZACIVSA-N (2r)-4,8-dimethoxy-9-methyl-2-propan-2-yl-2,3-dihydrofuro[2,3-b]quinolin-9-ium Chemical compound C[N+]1=C2C(OC)=CC=CC2=C(OC)C2=C1O[C@@H](C(C)C)C2 GUIBZZYABLMRRD-CQSZACIVSA-N 0.000 description 3
- 108010011619 6-Phytase Proteins 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 240000001592 Amaranthus caudatus Species 0.000 description 3
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 3
- 244000105624 Arachis hypogaea Species 0.000 description 3
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 3
- 235000006008 Brassica napus var napus Nutrition 0.000 description 3
- 240000000385 Brassica napus var. napus Species 0.000 description 3
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 3
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 3
- 244000045232 Canavalia ensiformis Species 0.000 description 3
- 235000005273 Canna coccinea Nutrition 0.000 description 3
- 240000008555 Canna flaccida Species 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 241000195628 Chlorophyta Species 0.000 description 3
- 241000223782 Ciliophora Species 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101500000018 Glycine max 2S albumin small chain Proteins 0.000 description 3
- 244000020551 Helianthus annuus Species 0.000 description 3
- 235000003222 Helianthus annuus Nutrition 0.000 description 3
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 3
- 244000043158 Lens esculenta Species 0.000 description 3
- 102000003820 Lipoxygenases Human genes 0.000 description 3
- 108090000128 Lipoxygenases Proteins 0.000 description 3
- 241000219997 Lonchocarpus Species 0.000 description 3
- 241000219745 Lupinus Species 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 206010064912 Malignant transformation Diseases 0.000 description 3
- 240000003183 Manihot esculenta Species 0.000 description 3
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 3
- 241000219823 Medicago Species 0.000 description 3
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 3
- 241001508788 Medicago scutellata Species 0.000 description 3
- 235000010617 Phaseolus lunatus Nutrition 0.000 description 3
- 241000219998 Philenoptera violacea Species 0.000 description 3
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 3
- 235000010582 Pisum sativum Nutrition 0.000 description 3
- 240000004713 Pisum sativum Species 0.000 description 3
- 235000010575 Pueraria lobata Nutrition 0.000 description 3
- 244000046146 Pueraria lobata Species 0.000 description 3
- 240000000111 Saccharum officinarum Species 0.000 description 3
- 235000007201 Saccharum officinarum Nutrition 0.000 description 3
- 241000209056 Secale Species 0.000 description 3
- 235000007238 Secale cereale Nutrition 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 3
- 235000009337 Spinacia oleracea Nutrition 0.000 description 3
- 244000300264 Spinacia oleracea Species 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 235000010749 Vicia faba Nutrition 0.000 description 3
- 240000006677 Vicia faba Species 0.000 description 3
- 235000002098 Vicia faba var. major Nutrition 0.000 description 3
- 241000219977 Vigna Species 0.000 description 3
- 235000010726 Vigna sinensis Nutrition 0.000 description 3
- 241000219995 Wisteria Species 0.000 description 3
- 239000004178 amaranth Substances 0.000 description 3
- 235000012735 amaranth Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000002518 antifoaming agent Substances 0.000 description 3
- 235000013527 bean curd Nutrition 0.000 description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
- 239000000920 calcium hydroxide Substances 0.000 description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000004042 decolorization Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 230000036212 malign transformation Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000019713 millet Nutrition 0.000 description 3
- 230000004220 muscle function Effects 0.000 description 3
- 201000006938 muscular dystrophy Diseases 0.000 description 3
- 150000003961 organosilicon compounds Chemical class 0.000 description 3
- 235000020232 peanut Nutrition 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000000467 phytic acid Substances 0.000 description 3
- 229940068041 phytic acid Drugs 0.000 description 3
- 235000002949 phytic acid Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000004627 regenerated cellulose Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000004576 sand Substances 0.000 description 3
- 235000013322 soy milk Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000617 Cathepsin G Proteins 0.000 description 2
- 102000004173 Cathepsin G Human genes 0.000 description 2
- 108090000227 Chymases Proteins 0.000 description 2
- 102000003858 Chymases Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108700037728 Glycine max beta-conglycinin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 244000291473 Musa acuminata Species 0.000 description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 2
- 206010040829 Skin discolouration Diseases 0.000 description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 240000004922 Vigna radiata Species 0.000 description 2
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 2
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003217 anti-cancerogenic effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 229940023913 cation exchange resins Drugs 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 244000013123 dwarf bean Species 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 108010083391 glycinin Proteins 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000003014 ion exchange membrane Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000010874 maintenance of protein location Effects 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000011140 membrane chromatography Methods 0.000 description 2
- 238000009285 membrane fouling Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 150000003377 silicon compounds Chemical class 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 230000025185 skeletal muscle atrophy Effects 0.000 description 2
- 208000013363 skeletal muscle disease Diseases 0.000 description 2
- 230000037370 skin discoloration Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- KSDTXRUIZMTBNV-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 KSDTXRUIZMTBNV-INIZCTEOSA-N 0.000 description 1
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 1
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- ZPGDWQNBZYOZTI-UHFFFAOYSA-N 1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000579895 Chlorostilbon Species 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000694440 Colpidium aqueous Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000221089 Jatropha Species 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 244000003167 Musa acuminata AAA Group Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000004179 Oral Leukoplakia Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 244000083398 Zea diploperennis Species 0.000 description 1
- 235000007241 Zea diploperennis Nutrition 0.000 description 1
- HHCTZPUNPCCKJV-UHFFFAOYSA-N [4-(2-carboxyethenyl)phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)C1=CC=C(C=CC(O)=O)C=C1 HHCTZPUNPCCKJV-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 108010019077 beta-Amylase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000010976 emerald Substances 0.000 description 1
- 229910052876 emerald Inorganic materials 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000021554 flavoured beverage Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- RKDYKIHMFYAPMZ-UHFFFAOYSA-N n-[5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]benzamide Chemical group C=1C=C([N+]([O-])=O)C=CC=1NC(=O)C(CCCN=C(N)N)NC(=O)C1=CC=CC=C1 RKDYKIHMFYAPMZ-UHFFFAOYSA-N 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 201000008557 oral mucosa leukoplakia Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013500 performance material Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000029255 peripheral nervous system cancer Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 229940085127 phytase Drugs 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 235000012434 pretzels Nutrition 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000020195 rice milk Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- XCHUIXZPWRRVAH-RRAJOLSVSA-M trimethyl-[4-[(e)-3-(4-methyl-2-oxochromen-7-yl)oxy-3-oxoprop-1-enyl]phenyl]azanium;chloride Chemical compound [Cl-].C1=CC=2C(C)=CC(=O)OC=2C=C1OC(=O)\C=C\C1=CC=C([N+](C)(C)C)C=C1 XCHUIXZPWRRVAH-RRAJOLSVSA-M 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 238000011816 wild-type C57Bl6 mouse Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/14—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from leguminous or other vegetable seeds; from press-cake or oil-bearing seeds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/14—Vegetable proteins
- A23J3/16—Vegetable proteins from soybean
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Dairy Products (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29131209P | 2009-12-30 | 2009-12-30 | |
| US61/291,312 | 2009-12-30 | ||
| PCT/US2010/062553 WO2011082335A2 (en) | 2009-12-30 | 2010-12-30 | Purified bowman-birk protease inhibitor proteins isolated from a soy processing stream |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013516427A true JP2013516427A (ja) | 2013-05-13 |
| JP2013516427A5 JP2013516427A5 (enExample) | 2014-02-13 |
Family
ID=44226820
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012547316A Pending JP2013516431A (ja) | 2009-12-30 | 2010-12-30 | 大豆加工ストリームから単離される精製Ｋｕｎｉｔｚトリプシンインヒビタータンパク質 |
| JP2012547309A Pending JP2013516427A (ja) | 2009-12-30 | 2010-12-30 | 大豆加工ストリームから単離される精製ボーマン・バークプロテアーゼインヒビタープロテイン |
| JP2012547311A Pending JP2013516429A (ja) | 2009-12-30 | 2010-12-30 | ボーマン・バークインヒビタープロテインを大豆加工ストリームから回収する方法 |
| JP2012547317A Pending JP2013516432A (ja) | 2009-12-30 | 2010-12-30 | 大豆加工ストリームからＫｕｎｉｔｚトリプシンインヒビタータンパク質を回収する方法 |
| JP2015118467A Abandoned JP2015157873A (ja) | 2009-12-30 | 2015-06-11 | 大豆加工ストリームから単離される精製Ｋｕｎｉｔｚトリプシンインヒビタータンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012547316A Pending JP2013516431A (ja) | 2009-12-30 | 2010-12-30 | 大豆加工ストリームから単離される精製Ｋｕｎｉｔｚトリプシンインヒビタータンパク質 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012547311A Pending JP2013516429A (ja) | 2009-12-30 | 2010-12-30 | ボーマン・バークインヒビタープロテインを大豆加工ストリームから回収する方法 |
| JP2012547317A Pending JP2013516432A (ja) | 2009-12-30 | 2010-12-30 | 大豆加工ストリームからＫｕｎｉｔｚトリプシンインヒビタータンパク質を回収する方法 |
| JP2015118467A Abandoned JP2015157873A (ja) | 2009-12-30 | 2015-06-11 | 大豆加工ストリームから単離される精製Ｋｕｎｉｔｚトリプシンインヒビタータンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US20130023649A1 (enExample) |
| EP (5) | EP2785730A1 (enExample) |
| JP (5) | JP2013516431A (enExample) |
| CN (6) | CN103988973A (enExample) |
| BR (2) | BR112012016232A2 (enExample) |
| CA (2) | CA2785736A1 (enExample) |
| WO (5) | WO2011082359A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ588603A (en) | 2008-03-26 | 2012-03-30 | Oramed Ltd | Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin |
| EP2725912A4 (en) * | 2011-06-29 | 2015-03-04 | Solae Llc | BAKERY COMPOSITIONS WITH SOYAMOL PROTEINS ISOLATED FROM PROCESSING STREAMS |
| WO2013114369A1 (en) * | 2012-02-01 | 2013-08-08 | Oramed Ltd | Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same |
| BR112015001581A2 (pt) * | 2012-07-26 | 2017-07-04 | Solae Llc | agente de emulsificação, produto para os cuidados pessoais, produto industrial, equipamento, método para a fabricação de um produto e agente de emulsificação de estabilização |
| CN104736001A (zh) * | 2012-07-26 | 2015-06-24 | 索莱有限责任公司 | 用于食品组合物中的发泡剂 |
| WO2014018922A1 (en) * | 2012-07-26 | 2014-01-30 | Solae, Llc | Emulsifying agent for use in food compositions |
| US20150246332A1 (en) * | 2012-07-26 | 2015-09-03 | Solac, LLC | Foaming agent for use in industrial products |
| US9765111B2 (en) | 2012-10-23 | 2017-09-19 | Upfront Chromatography A/S | Separation processes for soy protein |
| WO2014106846A2 (en) | 2013-01-03 | 2014-07-10 | Oramed Ltd. | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof |
| FR3001362B1 (fr) | 2013-01-31 | 2015-07-10 | Roquette Freres | Procede de fractionnement des solubles de pois, fractions obtenues et leur valorisation |
| CN103392907B (zh) * | 2013-06-08 | 2014-12-17 | 东北农业大学 | 酶法修饰改善乳清蛋白纳米纤维聚合量的方法 |
| WO2015101435A1 (en) * | 2013-12-30 | 2015-07-09 | Koninklijke Philips N.V. | A method of making soymilk |
| CA2937598A1 (en) * | 2014-01-29 | 2015-08-06 | Upfront Chromatography A/S | Novel separation processes for pea protein |
| CN103933548A (zh) * | 2014-04-17 | 2014-07-23 | 中国药科大学 | 露那辛多肽在防治白内障药物中的应用 |
| AU2016343738B2 (en) * | 2015-10-30 | 2021-05-13 | Beth Israel Deaconess Medical Center, Inc. | Methods for determination of bioactivity, quantity, removal, or inactivation of cereal amylase trypsin inhibitors in cereals, flours, plants, and complex foods |
| US10858390B2 (en) * | 2016-09-02 | 2020-12-08 | Cem Corporation | Use of excess carbodiimide for peptide synthesis at elevated temperatures |
| AU2018243407B2 (en) | 2017-03-31 | 2024-04-04 | J.R. Simplot Company | Potato protein powders |
| CN107488226A (zh) * | 2017-09-06 | 2017-12-19 | 成都晟博源生物工程有限公司 | 一种大豆胰蛋白酶抑制剂的提取方法 |
| CN110872140B (zh) * | 2018-09-03 | 2022-06-21 | 中国石油化工股份有限公司 | 危化品分离回收系统 |
| CN110104754B (zh) * | 2019-04-03 | 2022-03-29 | 江苏农林职业技术学院 | 一种豆制品废水废渣处理甲基橙染料废水的方法 |
| CN110551209A (zh) * | 2019-08-27 | 2019-12-10 | 合肥天汇孵化科技有限公司 | 一种基于大豆深加工废液以豆清水为原料粗提sbti蛋白工艺 |
| US20230002444A1 (en) * | 2019-11-20 | 2023-01-05 | Csl Behring Ag | Method for extracting a protein from a precipitate and method for precipitating impurities |
| JP2023515828A (ja) * | 2020-02-26 | 2023-04-14 | イート ジャスト， インコーポレイテッド | 限外濾過によるパルスタンパク質単離 |
| EP4165057A1 (en) * | 2020-06-12 | 2023-04-19 | Basf Se | Improved demineralization of fermentation broths and purification of fine chemicals such as oligosaccharides |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288856A (en) * | 1986-11-20 | 1994-02-22 | Pierre Amiguet | Method of isolating acid-stable, biologically active proteins |
| JP2007528212A (ja) * | 2003-11-06 | 2007-10-11 | ジェネンコー・インターナショナル・インク | 糸状菌におけるプロテアーゼ抑制剤及びその変異体の発現 |
| JP2008500805A (ja) * | 2003-11-06 | 2008-01-17 | ジェネンコー・インターナショナル・インク | プロテアーゼインヒビター及びそれらの変異体のバクテリア発現 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4368151A (en) * | 1981-08-10 | 1983-01-11 | A. E. Staley Manufacturing Company | 7S And 11S vegetable protein fractionation and isolation |
| US4808314A (en) * | 1987-09-18 | 1989-02-28 | Scripps Clinic And Research Foundation | Method for reducing bacterial endotoxin contamination in solutions of macromolecules |
| US5250515A (en) * | 1988-04-11 | 1993-10-05 | Monsanto Company | Method for improving the efficacy of insect toxins |
| TR24186A (tr) * | 1988-04-11 | 1991-05-30 | Monsanto Co | Hasere zehirlerinin etkinligini arttirmak icin yoentem |
| JPH06145198A (ja) * | 1992-03-30 | 1994-05-24 | Shokuhin Sangyo High Separeeshiyon Syst Gijutsu Kenkyu Kumiai | 大豆トリプシンインヒビターの製造方法 |
| DK46793D0 (da) * | 1993-04-26 | 1993-04-26 | Novo Nordisk As | Enzym |
| JPH1066572A (ja) * | 1996-08-29 | 1998-03-10 | Showa Sangyo Co Ltd | 高純度の大豆トリプシンインヒビターの製造方法 |
| US6313273B1 (en) * | 1999-08-25 | 2001-11-06 | Abbott Laboratories | Soy proteins and methods for their production |
| US7175869B2 (en) * | 2000-11-30 | 2007-02-13 | Kraft Foods Holdings, Inc. | Method of deflavoring soy-derived materials using electrodialysis |
| US6787173B2 (en) * | 2000-11-30 | 2004-09-07 | Kraft Foods Holdings, Inc. | Method of deflavoring soy-derived materials |
| CN1150831C (zh) * | 2001-01-19 | 2004-05-26 | 北京中联捷思科技发展有限公司 | 超滤提取大豆乳清蛋白的方法 |
| US6927322B2 (en) * | 2001-03-30 | 2005-08-09 | Cornell Research Foundation, Inc. | Cabbage proteinase inhibitor gene confers resistance against plant pests |
| US7214394B2 (en) * | 2002-05-31 | 2007-05-08 | Archer-Daniels-Midland Company | Policosanol compositions, extraction from novel sources, and uses thereof |
| CN100506062C (zh) * | 2002-08-28 | 2009-07-01 | 不二制油株式会社 | 酸性大豆蛋白质凝胶食物及其生产方法 |
| JPWO2004104036A1 (ja) * | 2003-05-21 | 2006-10-26 | 不二製油株式会社 | 大豆ホエー蛋白及び大豆ホエー蛋白分解物の製造法 |
| US20070277269A1 (en) * | 2006-04-17 | 2007-11-29 | Ceres, Inc. | Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics |
| CA2544898A1 (en) * | 2003-11-05 | 2005-05-19 | Kerry Group Services International, Ltd. | Acid-stable soy protein and fortified food or beverage |
| CN1615722A (zh) * | 2003-11-14 | 2005-05-18 | 哈高科大豆食品有限责任公司 | 超滤膜分离技术制备大豆分离蛋白的方法 |
| US20090269456A1 (en) * | 2004-02-26 | 2009-10-29 | Toshio Kiriyama | Soybean protein-containing solution and gel |
| EP1731160B1 (en) * | 2004-02-27 | 2012-07-11 | Fuji Oil Company, Ltd. | Cancer metastasis inhibitory composition |
| US20060057275A1 (en) * | 2004-09-16 | 2006-03-16 | Shaowen Wu | Process for the preparation of glycinin-rich and beta-conglycinin-rich protein fractions |
| BRPI0613548A2 (pt) * | 2005-05-05 | 2011-01-18 | Genencor Int | composições de cuidado pessoal e métodos para seu uso |
| US20070054031A1 (en) * | 2005-09-02 | 2007-03-08 | Keshun Liu | Methods of extracting, concentrating and fractionating proteins and other chemical components |
| TWI257723B (en) * | 2005-09-15 | 2006-07-01 | Epitech Technology Corp | Vertical light-emitting diode and method for manufacturing the same |
| US20080182002A1 (en) * | 2007-01-26 | 2008-07-31 | Solae, Llc | Processes for Removing Bitter Components from Soy Protein Isolates |
| US20090011083A1 (en) * | 2007-07-03 | 2009-01-08 | Solae, Llc | Modified Vegetable Protein Having Low Levels of Phytic Acid, Isoflavones and Ash |
| CN101367018A (zh) * | 2007-09-13 | 2009-02-18 | 中国海洋大学 | 壳聚糖树脂固定化酶纯化大豆乳清废水中胰蛋白酶抑制剂的工艺 |
| AU2008362898B2 (en) * | 2008-10-15 | 2013-02-28 | Danisco Us Inc. | Modified variant Bowman Birk Protease inhibitors |
-
2010
- 2010-12-30 WO PCT/US2010/062592 patent/WO2011082359A1/en not_active Ceased
- 2010-12-30 WO PCT/US2010/062556 patent/WO2011082338A1/en not_active Ceased
- 2010-12-30 US US13/519,842 patent/US20130023649A1/en not_active Abandoned
- 2010-12-30 JP JP2012547316A patent/JP2013516431A/ja active Pending
- 2010-12-30 WO PCT/US2010/062591 patent/WO2011082358A1/en not_active Ceased
- 2010-12-30 US US13/519,829 patent/US20120329993A1/en not_active Abandoned
- 2010-12-30 JP JP2012547309A patent/JP2013516427A/ja active Pending
- 2010-12-30 US US13/519,848 patent/US20120289683A1/en not_active Abandoned
- 2010-12-30 WO PCT/US2010/062594 patent/WO2011082360A1/en not_active Ceased
- 2010-12-30 JP JP2012547311A patent/JP2013516429A/ja active Pending
- 2010-12-30 EP EP10841760.1A patent/EP2785730A1/en not_active Withdrawn
- 2010-12-30 CN CN201410168443.1A patent/CN103988973A/zh active Pending
- 2010-12-30 WO PCT/US2010/062553 patent/WO2011082335A2/en not_active Ceased
- 2010-12-30 CN CN201080064208XA patent/CN102762584A/zh active Pending
- 2010-12-30 CA CA2785736A patent/CA2785736A1/en not_active Abandoned
- 2010-12-30 CN CN2010800648423A patent/CN102781459A/zh active Pending
- 2010-12-30 US US13/519,840 patent/US20120302736A1/en not_active Abandoned
- 2010-12-30 JP JP2012547317A patent/JP2013516432A/ja active Pending
- 2010-12-30 EP EP10841743.7A patent/EP2519535A4/en not_active Withdrawn
- 2010-12-30 CN CN2010800648368A patent/CN102770439A/zh active Pending
- 2010-12-30 EP EP10841740.3A patent/EP2519251A4/en not_active Withdrawn
- 2010-12-30 US US13/519,832 patent/US20130023480A1/en not_active Abandoned
- 2010-12-30 CA CA2785599A patent/CA2785599A1/en not_active Abandoned
- 2010-12-30 EP EP10841759.3A patent/EP2519245A4/en not_active Withdrawn
- 2010-12-30 BR BR112012016232A patent/BR112012016232A2/pt not_active IP Right Cessation
- 2010-12-30 BR BR112012016225A patent/BR112012016225A2/pt active Search and Examination
- 2010-12-30 CN CN201080064855.0A patent/CN102781255B/zh not_active Expired - Fee Related
- 2010-12-30 EP EP10841758.5A patent/EP2519117A4/en not_active Withdrawn
- 2010-12-30 CN CN2010800642291A patent/CN102770147A/zh active Pending
-
2015
- 2015-06-11 JP JP2015118467A patent/JP2015157873A/ja not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288856A (en) * | 1986-11-20 | 1994-02-22 | Pierre Amiguet | Method of isolating acid-stable, biologically active proteins |
| JP2007528212A (ja) * | 2003-11-06 | 2007-10-11 | ジェネンコー・インターナショナル・インク | 糸状菌におけるプロテアーゼ抑制剤及びその変異体の発現 |
| JP2008500805A (ja) * | 2003-11-06 | 2008-01-17 | ジェネンコー・インターナショナル・インク | プロテアーゼインヒビター及びそれらの変異体のバクテリア発現 |
Non-Patent Citations (3)
| Title |
|---|
| JPN6015050697; Ｌｉｕ Ｓ ｅｔ ａｌ．: 'Ｒｅｍｏｖａｌ ｏｆ ｅｎｄｏｔｏｘｉｎ ｆｒｏｍ ｒｅｃｏｍｂｉｎａｎｔ ｐｒｏｔｅｉｎ ｐｒｅｐａｒａｔｉｏｎｓ．' Ｃｌｉｎ Ｂｉｏｃｈｅｍ． ３０（６）, 199708, ４５５-４６３ * |
| JPN6015050699; Ｚａｃｈｏｖａ Ｋ ｅｔ ａｌ．: 'Ｎｏｖｅｌ ｍｏｄｉｆｉｃａｔｉｏｎ ｏｆ ｇｒｏｗｔｈ ｍｅｄｉｕｍ ｅｎａｂｌｅｓ ｅｆｆｉｃｉｅｎｔ Ｅ． ｃｏｌｉ ｅｘｐｒｅｓｓｉｏｎ ａｎｄ ｓｉｍｐｌｅ ｐｕｒｉｆｉｃａｔｉｏｎ ｏｆ' Ｊ Ｍｉｃｒｏｂｉｏｌ Ｂｉｏｔｅｃｈｎｏｌ． １９（７）, 200907, ７２７-３３ * |
| JPN6015050701; Ｐｅｔｓｃｈ Ｄ: 'Ｅｎｄｏｔｏｘｉｎ ｒｅｍｏｖａｌ ｆｒｏｍ ｐｒｏｔｅｉｎ ｓｏｌｕｔｉｏｎｓ．' Ｊ Ｂｉｏｔｅｃｈｎｏｌ ７６（２-３）, 20000121, ９７-１１９ * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516427A (ja) | 大豆加工ストリームから単離される精製ボーマン・バークプロテアーゼインヒビタープロテイン | |
| EP2681231B1 (en) | Method for isolating osteopontin using concentrated feeds | |
| Wu et al. | Simultaneous production of multi-functional peptides by pancreatic hydrolysis of bovine casein in an enzymatic membrane reactor via combinational chromatography | |
| CA2611416A1 (en) | Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method for the production thereof | |
| US7371418B2 (en) | Method for controlling the yield and purity of proteinase inhibitor II during extraction | |
| KR20140026295A (ko) | 안지오텐신-i 전환 효소 저해능을 나타내는 펩타이드를 유효성분으로 포함하는 심혈관계 질환 예방 또는 치료용 약학적 조성물 | |
| CN104693272B (zh) | 牦牛乳乳清蛋白具有抗氧化活性的三肽及其应用和组合物 | |
| WO2003003835A1 (en) | Method for controlling the yield and purity of proteinase inhibitor ii during extraction | |
| Kong et al. | Purification of soybean Kunitz trypsin inhibitor and the mechanism of its passivation by lysine and disulfide bond modifications | |
| AU2009254570A1 (en) | Anxiolytic composition containing alphas1-casein-derived peptides | |
| WO2003003836A1 (en) | Method for the elimination of kunitz and bowman-birk trypsin inhibitors and carboxydase inhibitor from potato proteins | |
| Salvado et al. | Enzymatic production of bioactive peptides from whey proteins: Their active role and potential health benefits | |
| CN118324858B (zh) | 一种具有dpp-iv抑制活性的富硒松花粉肽及其应用 | |
| JP2000086530A (ja) | 新規トリプシンインヒビター | |
| NZ614874B2 (en) | Method for isolating osteopontin using concentrated feeds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150209 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150806 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20151216 |